Zydus Lifesciences Ltd Share Price
(ZYDUSLIFE)
₹886.4
as on 04:01PM, 28 Mar 2025
🔔 Acquisition Alert
Zydus Family Trust acquires luxury apartment in Mumbai's Worli for Rs 200 crore.
Zydus Lifesciences Performance
Day's Low
Day's High
₹880.55Day's Price Range₹900.5552 Week's Low
52 Week's High
₹855.152-Week Price Range₹1,324.3
| Returns % | |
| 1 Month Return | + 1.61 % |
| 3 Month Return | -6.92 % |
| 1 Year Return | -11.57 % |
| Market Stats | |
| Previous Close | ₹890.75 |
| Open | ₹894.90 |
| Volume | 12.45L |
| Upper Circuit | ₹979.80 |
| Lower Circuit | ₹801.70 |
| Market Cap | ₹89,630.29Cr |
Zydus Lifesciences Fundamentals
P/E Ratio
19.78
PEG Ratio
1.26
Market Cap
₹89,630.29 Cr
P/B Ratio
6.43
EPS
38.31
Dividend Yield
0.3
Sector
Pharmaceuticals
ROE
23.45
Mutual Fund Holdings of Zydus Lifesciences
Zydus Lifesciences Analyst Rating
based on 31 analysts
48.39%
Buy
32.26%
Hold
19.35%
Sell
Based on 31 analysts offering long term price targets for Zydus Lifesciences. An average target of ₹1063.68
Source: S&P Global Market Intelligence
Zydus Lifesciences Share analysis
Zydus Lifesciences price forecast by 31 analysts
Upside of19.41%
High
₹1365
Target
₹1063.68
Low
₹840
Zydus Lifesciences target price ₹1063.68, a slight upside of 19.41% compared to current price of ₹886.4. According to 31 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Zydus Lifesciences revenue growth forecast
Expected growth rate Q1, FY2027:30.83%
Forecast
Actual
Including amortisation and stock based compensations
Zydus Lifesciences EPS growth forecast
EPS estimate Q1, FY2027:15.93%
Forecast
Actual
Source: S&P Global Market Intelligence
What's happening today
Today's Timeline - Invalid Date
02:24 PM
-Zydus Lifesciences announces loss of a share certificate, plans to issue a duplicate if no objections arise within seven days.
Key events for Zydus Lifesciences Ltd
Zydus Lifesciences Reports Share Certificate Loss - 28 Mar, 2025
Zydus Lifesciences Limited has reported the loss of a share certificate and will issue a duplicate if no objections are received within a week.Positive Outlook for Zydus Lifesciences Stock - 21 Mar, 2025
Zydus Lifesciences stock is recommended for buying in the range of Rs 900-922, with a target of Rs 1024 in one month. A favorable risk-reward setup is noted, supported by a recent buy signal from weekly stochastic indicators.Zydus Lifesciences Secures FDA Approval for Apalutamide - 18 Mar, 2025
Zydus Lifesciences has received final USFDA approval to manufacture Apalutamide Tablets, 60 mg, indicated for metastatic castration-sensitive prostate cancer, with significant market potential.Zydus Gains USFDA Approval and Inspection Success - 16 Mar, 2025
Zydus Lifesciences achieved a significant milestone by receiving USFDA approval for Eluxadoline Tablets, alongside a successful inspection at its Ankleshwar facility, enhancing its market position.Zydus Lifesciences Passes USFDA Inspection Successfully - 15 Mar, 2025
Zydus Lifesciences announced the successful completion of a USFDA inspection at its Ankleshwar API Unit, concluding with no observations. This achievement highlights the company's commitment to quality and compliance, potentially boosting investor confidence.Zydus Lifesciences Pursues Growth Through Acquisitions - 14 Mar, 2025
Zydus Lifesciences aims to drive growth by expanding its product portfolio and acquiring Amplitude Surgical. Despite recent underperformance against the BSE Healthcare Index, the acquisition could enhance its medtech presence.Zydus Lifesciences Expands with Acquisition and FDA Approval - 12 Mar, 2025
Zydus Lifesciences announced plans to acquire a controlling stake in Amplitude Surgical for Euro 256.8 million and received USFDA approval for its generic Methenamine Hippurate tablets, enhancing its product portfolio.Zydus Lifesciences Pursues Major Acquisition in MedTech - 11 Mar, 2025
Zydus Lifesciences has initiated exclusive negotiations to acquire an 85.6% stake in France's Amplitude Surgical for €256.8 million, with plans for a total acquisition value of €300 million. This move marks Zydus's entry into the global medical devices market, focusing on orthopedic implants and other sectors.Zydus Secures USFDA Approval and Government Support - 10 Mar, 2025
Zydus Lifesciences received USFDA approval for Ketoconazole Shampoo, reporting a significant profit increase in Q3 FY25. The chairman highlighted a new government incentive policy for pharma research.Zydus Lifesciences Gains FDA Approval for Dasatinib - 06 Mar, 2025
Zydus Lifesciences shares surged after receiving US FDA approval for Dasatinib tablets, a treatment for chronic myeloid leukemia, generating significant annual sales. The company reported a 29.62% increase in net profit for Q3 FY25.Zydus Lifesciences Launches New Drug and Gains Approval - 05 Mar, 2025
Zydus Lifesciences launched ANVIMO for transplant patients, reducing CMV prophylaxis costs by 91%. Additionally, they received USFDA approval for Dasatinib Tablets, enhancing their product portfolio.Zydus Develops First Combination Vaccine for Children - 04 Mar, 2025
Zydus Lifesciences announced plans to develop the first-ever combination vaccine for shigellosis and typhoid, aimed at protecting children under five, with support from the Gates Foundation. The project is set to begin in March 2025.Zydus Lifesciences Faces Short-Term Challenges - 03 Mar, 2025
Zydus Lifesciences is trading at a PE of 19.7, below its 10-year median. ICICI Securities sets a target price of Rs 1,000, indicating a potential 13.2% upside. While facing short-term challenges in the US market, domestic growth remains steady across various therapeutic areas.Zydus Lifesciences Reports Revenue Growth Amid Stock Decline - 02 Mar, 2025
Zydus Lifesciences' stock fell 2.2% to Rs. 867.3, despite a market cap of Rs. 88,166 crores. The company reported a 17% YoY revenue growth and a 30% YoY increase in net profit for Q3 FY25, indicating strong financial performance.Zydus Lifesciences Advocates Global Collaboration - 28 Feb, 2025
Zydus Lifesciences Chairman Pankaj R Patel emphasized the need for global collaboration to ensure a stable supply chain and encouraged drugmakers to adopt new technologies, referencing China's advancements in AI.
Insights on Zydus Lifesciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 3 Years
In the last 3 years, ZYDUSLIFE has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 7.52% to 7.53% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 5.30K Cr → 5.32K Cr (in ₹), with an average increase of 0.4% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 911.2 Cr → 1.02K Cr (in ₹), with an average increase of 11.0% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 70.5% return, outperforming this stock by 82.0%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 74.98% of holdings in Dec 2024 quarter
NEGATIVE IMPACTPrice Dip
In the last 3 months, ZYDUSLIFE stock has moved down by -6.9%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.85% to 6.84% in Dec 2024 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 6.57% to 6.32% in Dec 2024 quarter
Zydus Lifesciences Financials
Zydus Lifesciences Index Inclusions
Zydus Lifesciences Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 74.98% | 0.00 | |
| Foreign Institutions | 7.53% | 0.15 | |
| Mutual Funds | 6.32% | ||
| Retail Investors | 6.84% | ||
| Others | 4.34% | 6.30 |
Zydus Lifesciences Key Indicators
Zydus Lifesciences Valuation
Zydus Lifesciences in the last 5 years
Lowest (7.34x)
March 7, 2022
Today (19.78x)
March 27, 2025
Industry (53.19x)
March 27, 2025
Highest (34.62x)
March 26, 2024
Zydus Lifesciences Earnings and Dividends
Zydus Lifesciences Ltd Earnings Results
Zydus Lifesciences Ltd’s net profit jumped 29.62% since last year same period to ₹1,023.50Cr in the Q3 2024-2025. On a quarterly growth basis, Zydus Lifesciences Ltd has generated 12.32% jump in its net profits since last 3-months.
Read More about Earnings ResultsZydus Lifesciences Ltd Dividends May,2024
In the quarter ending March 2024, Zydus Lifesciences Ltd has declared dividend of ₹3 - translating a dividend yield of 1.02%.
Read More about Dividends
Zydus Lifesciences Technicals Summary
Bearish
Neutral
Bullish
Zydus Lifesciences Ltd is currently in a Bearish trading position according to technical analysis indicators.
Zydus Lifesciences Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹89,630.29 Cr | 50.65% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹13,456.77 Cr | -1.32% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹68,217.90 Cr | 39.78% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| BUY | ₹64,959.44 Cr | 20.19% | 0.53 | NA | NA | |
| BUY | ₹48,058.80 Cr | 26.23% | 0.56 | ₹589 Cr | ₹3,453 Cr |
About Zydus Lifesciences
The company has a strong presence in the global market and is known for its high-quality pharmaceutical products. It manufactures a wide range of generic and specialty drugs, including cardiovascular, anti-infective, anti-diabetic, and oncology medicines. Zydus also produces over-the-counter products and nutritional supplements. Some of its top products include Zetia, Atorvastatin, and Metformin.
Zydus Lifesciences Ltd is also known for its popular brands, such as Cadila, Nutralite, and Zydus Wellness. The company has a strong presence in the Indian market, with its products being sold in more than 20,000 stores across the country. It also exports its products to over 100 countries worldwide.
Revenue: ₹5,123.50Cr as on December 2024 (Q4 24)
Net Profit: ₹1,004.30Cr as on December 2024 (Q4 24)
Listing date: 18 Apr, 2000
Chairperson Name: Pankaj R Patel
| Organisation | Zydus Lifesciences |
| Headquarters | Ahmedabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Zydus Lifesciences Ltd
What is Zydus Lifesciences Ltd price today?
Zydus Lifesciences Ltd share price today stands at ₹886.4, Open: ₹894.9, Previous Close: ₹890.75, High: ₹900.55, Low: ₹880.55, 52 Week High: ₹1324.3, 52 Week Low: ₹855.1.
How to Buy Zydus Lifesciences Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Zydus Lifesciences Ltd shares
What are today's traded volumes of Zydus Lifesciences Ltd?
Today's traded volume of Zydus Lifesciences Ltd(ZYDUSLIFE) is 12.45L.
What is today's market capitalisation of Zydus Lifesciences Ltd?
Today's market capitalisation of Zydus Lifesciences Ltd(ZYDUSLIFE) is ₹89630.29Cr.
What is the 52 Week High and Low Range of Zydus Lifesciences Ltd?
How much percentage Zydus Lifesciences Ltd is down from its 52 Week High?
Zydus Lifesciences Ltd (ZYDUSLIFE) share price is ₹886.4. It is down -33.07% from its 52 Week High price of ₹1324.3
How much percentage Zydus Lifesciences Ltd is up from its 52 Week low?
Zydus Lifesciences Ltd (ZYDUSLIFE) share price is ₹886.4. It is up 3.66% from its 52 Week Low price of ₹855.1